Figure 1.

The effect of bevacizumab (Bev) treatment on overall survival by mismatch repair (MMR) status for colon cancer: NSABP C-08. A) MMR deficient. B) MMR proficient. In each panel, the survival estimates are derived by the Kaplan–Meier method, and the hazard ratio (HR), confidence intervals (CIs), and P value come from a Cox regression model containing only an indicator variable for treatment. The MMR–treatment interaction test (P = 0.04) is from a Cox regression model including indicator variables for MMR, bevacizumab treatment, and the interaction term. All statistical tests were two-sided. mFF6 = modified FOLFOX6.